S100A6

(redirected from CABP)
Also found in: Acronyms.

S100A6

A gene on chromosome 1q21 that encodes a member of the S100 family of proteins, which have 2 EF-hand calcium-binding motifs. S100 proteins are localised in the cytoplasm and/or nucleus of a wide range of cells; they are involved in regulating cell cycle progression, differentiation and other intracellular activities. S100A6 is thought to play a role in stimulating Ca2+-dependent insulin release, stimulating prolactin secretion, and exocytosis.
Mentioned in ?
References in periodicals archive ?
The 2007 IDSA/ATS guidelines recommend broad-spectrum coverage for many patients with CABP, including those with comorbidities or other risks for drug-resistant S pneumoniae.
As a surgeon who has been independently practising LABP as an alternative to CABP since 1995, Dr Rangaswamy has seen complication rates brought down to five per cent.
Beard to Max Farrand, May 5,1913, DC 572--Correspondence A-F, Folder 21: Farrand, Max (Huntington Library), 1913-36, CABP.
which includes research with 50 infectious diseases specialists and 51 critical care/internists physicians, analyzes the usage and uptake of antibiotics for the treatment of patients diagnosed with CABP and NP, including hospital-acquired pneumonia, healthcare-associated pneumonia, and ventilator-associated pneumonia in the hospital setting.
This partnership will create an electronic platform to validate key PROs, allowing investigators to assess the symptoms of ABSSSI, CABP and HABP at various time points over the course of the infection and measure the effects of antibacterial drugs.
The primary factor constraining the CABP market through 2021 is the generic erosion of several key antibiotics--moxifloxacin (Bayer/Merck's Avelox), doripenem (Shionogi's Finibax, Janssen's Doribax), ertapenem (Merck's Invanz), linezolid (Pfizer's Zyvox) and tigecycline (Pfizer's Tygacil).
Mark Leuchtenberger, Chief Executive Officer of Rib-X said, "The need for antibiotics that safely treat a broader spectrum of infections, not to mention those which have shown resistance to linezolid, is growing and radezolid has thus far succeeded in addressing a diverse set of challenges in ABSSSI and CABP.
What factors are driving the market for CABP therapies?
Before the end of 2015, the company plans to have initiated its second pivotal Phase 3 clinical study to assess the safety and efficacy of omadacycline in the treatment of CABP.
M2 EQUITYBITES-September 3, 2015-Allergan awarded US FDA approval for sNDA for the updated label for TEFLARO for the treatment of ABSSSI and CABP
M2 PHARMA-September 3, 2015-Allergan awarded US FDA approval for sNDA for the updated label for TEFLARO for the treatment of ABSSSI and CABP
Presently, the product is in Phase III development for the treatment of CABP and submission of a new drug application is planned for 2016.